MALAT1 and central nervous system cancer: The downregulation of MALAT1 reduces the mRNA expression levels of multidrug resistance-related proteins such as multidrug resistance protein 1 (MDR1), multidrug resistance protein 5 (MRP5), and lung–resistance related protein 1 (LRP1), which are important regulators of chemoresistance, and also reduces glioma cell sensitivity to TMZ.